127 related articles for article (PubMed ID: 2201071)
1. Zidovudine intolerance.
Groopman JE
Rev Infect Dis; 1990; 12 Suppl 5():S500-6. PubMed ID: 2201071
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic growth factors as adjuncts to antiretroviral therapy.
Miles SA
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1073-80. PubMed ID: 1380256
[TBL] [Abstract][Full Text] [Related]
3. Hematologic toxicity of zidovudine in HIV-infected patients.
Brogan KL; Zell SC
Am Fam Physician; 1990 May; 41(5):1521-8. PubMed ID: 1692180
[TBL] [Abstract][Full Text] [Related]
4. The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies.
Miles SA
Cancer Invest; 1991; 9(2):229-38. PubMed ID: 1713806
[TBL] [Abstract][Full Text] [Related]
5. Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection.
Chen SC; Barker SM; Mitchell DH; Stevens SM; O'Neill P; Cunningham AL
Pathology; 1992 Apr; 24(2):109-11. PubMed ID: 1641255
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. Australian Zidovudine Study Group.
Swanson CE; Tindall B; Cooper DA
AIDS; 1994 May; 8(5):625-34. PubMed ID: 8060543
[TBL] [Abstract][Full Text] [Related]
7. A cost analysis of approved antiretroviral strategies in persons with advanced human immunodeficiency virus disease and zidovudine intolerance.
Bozzette SA; Parker R; Hay J
J Acquir Immune Defic Syndr (1988); 1994 Apr; 7(4):355-62. PubMed ID: 7510808
[TBL] [Abstract][Full Text] [Related]
8. Prevention of hematopoietic myeloid and megakaryocyte toxicity associated with zidovudine in vivo in mice with recombinant GM-CSF.
Gallicchio VS; Hughes NK; Tse KF
Growth Regul; 1994 Jun; 4(2):41-7. PubMed ID: 7950902
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor and zidovudine in the treatment of neutropenia and human immunodeficiency virus infection.
Hewitt RG; Morse GD
Pharmacotherapy; 1992; 12(6):455-61. PubMed ID: 1492010
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy with zidovudine, recombinant granulocyte colony stimulating factors and erythropoietin in asymptomatic HIV patients.
Perrella O; Finelli E; Perrella A; Tartaglia G; Scognamiglio P; Scalera G
J Chemother; 1996 Feb; 8(1):63-6. PubMed ID: 8835112
[TBL] [Abstract][Full Text] [Related]
11. Management of the hematologic complications of human immunodeficiency virus infection.
Groopman JE
Rev Infect Dis; 1990; 12(5):931-7. PubMed ID: 2237134
[TBL] [Abstract][Full Text] [Related]
12. [Anti-retroviral therapy of HIV-infection. With preliminary results of the Swiss postmarketing surveillance of zidovudine].
Jost J; Lüthy R
Schweiz Med Wochenschr; 1991 Apr; 121(16):555-65. PubMed ID: 1904164
[TBL] [Abstract][Full Text] [Related]
13. [Muscular complications in HIV infection].
Authier FJ; Chariot P; Gherardi R
Arch Anat Cytol Pathol; 1997; 45(2-3):174-8. PubMed ID: 9382610
[TBL] [Abstract][Full Text] [Related]
14. HIV or zidovudine myopathy?
Kieburtz K
Neurology; 1994 Feb; 44(2):361; author reply 362-4. PubMed ID: 8309596
[No Abstract] [Full Text] [Related]
15. Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1.
Scadden DT; Pickus O; Hammer SM; Stretcher B; Bresnahan J; Gere J; McGrath J; Agosti JM
AIDS Res Hum Retroviruses; 1996 Aug; 12(12):1151-9. PubMed ID: 8844019
[TBL] [Abstract][Full Text] [Related]
16. [The treatment of 12 HIV-infected children with zidovudine].
Scherpbier HJ; Prakken AB; de Graeff-Meeder ER; van den Berg H
Ned Tijdschr Geneeskd; 1993 Aug; 137(32):1610-3. PubMed ID: 8366963
[TBL] [Abstract][Full Text] [Related]
17. The use of hematopoietic hormones in HIV infection and AIDS-related malignancies.
Miles SA; Golde DW; Mitsuyasu RT
Hematol Oncol Clin North Am; 1991 Apr; 5(2):267-80. PubMed ID: 2022593
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection.
Davey RT; Davey VJ; Metcalf JA; Zurlo JJ; Kovacs JA; Falloon J; Polis MA; Zunich KM; Masur H; Lane HC
J Infect Dis; 1991 Jul; 164(1):43-52. PubMed ID: 1676045
[TBL] [Abstract][Full Text] [Related]
19. Zidovudine therapy and myopathies associated with human immunodeficiency virus infection.
Chariot P; Ruet E; Gherardi R
Ann Neurol; 1994 Feb; 35(2):247-8. PubMed ID: 8109910
[No Abstract] [Full Text] [Related]
20. Prognosis in AZT myopathy.
Chalmers AC; Greco CM; Miller RG
Neurology; 1991 Aug; 41(8):1181-4. PubMed ID: 1714057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
